- Standard panels measure cholesterol content. Arteries are damaged by particle count. ApoB counts particles, and it predicts risk better than LDL-C.
- Roughly one in five people has discordant results — an acceptable LDL-C alongside a genuinely elevated ApoB. Those people are told they are fine.
- Lp(a) is almost entirely genetic, affects around one in five people, and is measured once in a lifetime. Most people have never had it run.
- A normal cholesterol panel is not a clean bill of health. My own father-in-law had one, and had a heart attack at sixty-one.
- Insulin resistance and inflammation change everything about how these numbers should be read, which is why we never read a lipid panel alone.
Why this one is personal
My father-in-law had his cholesterol checked. The numbers came back within range and he was told he was fine. At sixty-one he had a heart attack.
What I have learned since is that his panel was never wrong — it was incomplete. The test he was given measures how much cholesterol is being carried through the blood. It does not measure how many particles are doing the carrying, and it does not measure Lp(a) at all. Both of those are better predictors of what actually happens to an artery.
That is why this is one of the panels I am most insistent about, and why I want every patient over forty to have run it at least once.
Particles versus content, and why it matters
This distinction is the whole article, and once you see it you cannot unsee it.
Cholesterol does not travel loose in your blood. It is carried inside particles, and each of those particles has exactly one apolipoprotein B molecule on its surface. One ApoB, one particle. So measuring ApoB counts your particles directly.
LDL-C, the number on a standard panel, measures the cholesterol contained within those particles. And here is the problem: particles vary enormously in how much cholesterol each one carries. Two people can have identical LDL-C with completely different particle counts.
Every one of those particles can penetrate and lodge in an artery wall. That is how plaque begins. So what determines risk is how many are circulating, not how much cargo each is carrying — and roughly one in five people has an LDL-C that looks acceptable alongside an ApoB that is genuinely elevated.
Those people are told their cholesterol is fine. It is exactly the group I worry about most.
Lp(a): the test almost nobody runs
If you take one thing from this page, make it this. Lipoprotein(a) affects around one in five people, is largely determined by genetics, and most people have never had it measured once.
Lp(a) is an LDL particle with an additional protein attached. That structure makes it substantially more likely to lodge in an artery wall and more prone to promoting clotting. It is an independent risk factor for heart attack and stroke, and it is not meaningfully influenced by diet or exercise.
Which raises a fair question: why measure something you cannot change with lifestyle?
Because it changes everything about how aggressively everything else should be managed. Someone with high Lp(a) needs their ApoB, blood pressure and inflammatory markers driven considerably lower than someone without it. It also explains family histories that otherwise make no sense — the relative who had a heart attack in their fifties while doing everything right.
It needs measuring once. The level is largely fixed for life. One test, once, and you know something about your risk that no other marker will tell you.
The panel we run
The ten levers that lower cardiovascular risk
Ranked by effect size and how reliably we see them work.
Get ApoB Measured, Then Manage To It
You cannot manage a number nobody has run. ApoB is inexpensive, widely available and a better predictor than the panel most people receive. Managing to ApoB rather than LDL-C is the single most useful change in this entire field.
What the evidence showsEvery atherogenic lipoprotein particle carries exactly one apolipoprotein B molecule, so ApoB is a direct particle count. Sniderman and colleagues demonstrated ApoB predicts cardiovascular events better than LDL cholesterol in a JAMA Cardiology review.Measure Lp(a) Once
One test, once in a lifetime, that tells you something no other marker will. It affects roughly one in five people and it changes how aggressively every other number should be managed.
What the evidence showsLipoprotein(a) is approximately 80 to 90 percent genetically determined, affects roughly one in five people, and is an independent causal risk factor for myocardial infarction and aortic stenosis established through Mendelian randomisation studies.Address Insulin Resistance
Insulin resistance drives small dense particles, raises triglycerides and lowers HDL. It sits upstream of most of the lipid picture, which is why correcting it often improves several numbers at once.
What the evidence showsInsulin resistance drives production of small dense LDL particles, raises triglycerides and lowers HDL — producing a high particle count at any given LDL cholesterol level, which is the discordance that makes standard panels misleading.Lower Inflammation
Particles cause the damage, but inflammation determines how much damage they do. An hs-CRP above 3 substantially changes the risk picture at any given ApoB, and it is modifiable.
What the evidence showsThe CANTOS trial demonstrated that reducing inflammation with canakinumab lowered cardiovascular events independent of any lipid change, establishing inflammation as a causal contributor rather than a marker.Fibre, Genuinely Enough of It
Soluble fibre binds bile acids and forces the liver to use cholesterol to make more, which lowers circulating particles. Most people eat around half of what is needed for this effect. Oats, legumes, psyllium, ground flax.
What the evidence showsSoluble fibre binds bile acids in the intestine, forcing hepatic cholesterol conversion to replace them and upregulating LDL receptor expression. Meta-analyses consistently show LDL reduction with soluble fibre intake.Resistance Training and Muscle
Muscle improves insulin sensitivity, which improves the entire lipid picture. It also raises HDL and lowers triglycerides independently. Two to three sessions weekly is the dose.
What the evidence showsResistance training improves insulin sensitivity, raises HDL and lowers triglycerides independently of weight change, and skeletal muscle is the primary site of insulin-mediated glucose disposal.Raise the Omega-3 Index
Modifiable within about four months and associated with lower cardiovascular mortality. Measured rather than assumed, because the dose needed to reach 8 percent varies enormously between people.
What the evidence showsPooled analysis of 17 prospective cohorts found higher blood omega-3 levels associated with lower total and cause-specific mortality. Red cell membrane turnover means the omega-3 index reflects roughly four months of intake.Correct the Thyroid
Hypothyroidism raises LDL and ApoB directly, and we have seen lipid panels normalise entirely once thyroid function was properly addressed. This is routinely missed because the two are managed by different people.
What the evidence showsHypothyroidism raises LDL and ApoB through reduced LDL receptor expression, and lipid abnormalities frequently resolve entirely with adequate thyroid treatment.Lower Homocysteine
An independent vascular risk factor that responds to methylated B12, folate and B6. Rarely measured, cheap to correct, and it also matters for cognition.
What the evidence showsElevated homocysteine is an independent vascular risk factor associated with endothelial dysfunction, and it responds to methylated B12, folate and B6 in patients with impaired methylation.Have the Medication Conversation Properly
For some patients, particularly those with high Lp(a) or established disease, medication is genuinely the right call, and that is a discussion for you and your physician. What we can do is make sure that decision is made from a complete picture rather than from an incomplete panel.
What the evidence showsFor patients with established disease or elevated Lp(a), lipid-lowering therapy has strong outcome evidence. The decision benefits from a complete picture including ApoB, Lp(a), hs-CRP and insulin rather than LDL-C alone.What patients commonly experience under our care
When patients receive the proper guidance, here is what they commonly experience under our care.
- Weeks 4–8 — triglycerides and insulin. The fastest-moving numbers. Reducing refined carbohydrate and adding fibre and resistance training changes triglycerides and fasting insulin before anything else shifts.
- Weeks 8–12 — ApoB and hs-CRP. This is the retest that matters. ApoB responds to fibre, weight change and insulin improvement, and hs-CRP falls as the inflammatory load comes down.
- Months 3–4 — omega-3 index. Red blood cell membranes turn over on roughly a four-month cycle, so this is when the omega-3 index reflects what you have been doing rather than where you started.
- Ongoing — the number that does not change. Lp(a) stays where it is, and that is fine. Knowing it means we manage everything else to a target set by your actual risk rather than by a population average.
If you have been told your cholesterol is fine but you have a family history that worries you, please get ApoB and Lp(a) measured. Schedule a consultation and let my team run the panel that actually predicts risk. This is the one I am most insistent about, for reasons that are personal as well as clinical.
ApoB, Lp(a), hs-CRP, fasting insulin and the omega-3 index — the numbers a standard cholesterol panel leaves out.
Common questions
What is ApoB and why does it matter more than LDL?
Every cholesterol-carrying particle has exactly one apolipoprotein B molecule on its surface, so measuring ApoB counts your particles directly. LDL-C measures the cholesterol contained within those particles instead. Because particles vary in how much cholesterol each carries, two people with identical LDL-C can have very different particle counts — and it is particle number that drives arterial damage. ApoB is the better predictor and it is what we manage to.
Should I get my Lp(a) tested?
Yes, once. Lp(a) is largely genetic, affects roughly one in five people, and is an independent risk factor for heart attack and stroke. Because the level is essentially fixed for life, one test is all you need — and it changes how aggressively every other risk factor should be managed. Most people have never had it measured.
Can I have a normal cholesterol panel and still be at risk?
Yes, and this is the group we worry about most. Around one in five people has an acceptable LDL-C alongside a genuinely elevated ApoB. Add an unmeasured Lp(a) and you have someone being told they are fine while carrying real risk. A normal standard panel is not a clean bill of health.
What is an optimal ApoB level?
We target under 80 mg/dL for most patients, and lower where Lp(a) is elevated, where there is established disease or where family history is significant. Conventional cut-offs are considerably more permissive, which is one of the reasons we read these numbers against optimal ranges rather than laboratory reference ranges.
Do I need a statin?
That is a decision for you and your prescribing physician, and for some patients — particularly with high Lp(a) or established disease — medication is genuinely appropriate. What we would say is that the decision should be made from a complete picture including ApoB, Lp(a), hs-CRP and insulin, rather than from a standard panel that leaves out the numbers that predict risk best.
- Sniderman AD, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiology. 2019;4(12):1287–1295. PMID 31642874
- Marston NA, et al. Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction. JAMA Cardiology. 2022;7(3):250–256.
- Tsimikas S. A test in context: lipoprotein(a). Journal of the American College of Cardiology. 2017;69(6):692–711.
- Ridker PM, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease (CANTOS). New England Journal of Medicine. 2017;377(12):1119–1131.
- Harris WS, Tintle NL, Imamura F, et al. Blood n-3 fatty acid levels and total and cause-specific mortality from 17 prospective studies. Nature Communications. 2021;12:2329. PMC8062567
This article is educational and reflects the published literature as of August 2026. It is not a diagnosis or a treatment recommendation for any individual, and any decision about your care belongs in a conversation with a licensed practitioner who has seen your history and your labs.